drugset / Trial / NCT01575470

Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells

NCT01575470

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if bone marrow harvest, BMMNC separation, and re-infusion in adults with acute severe TBI is safe and will improve functional outcome. 12/09/2015 Update: The study is closed to new enrollment and all follow-up visits have been completed. Data analysis is underway.

Timeline

Start
2012-03
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow mononuclear cells Cell therapy 6e+06 cells/kg Intravenous
Subject autologous bone marrow mononuclear cells Cell therapy 9e+06 cells/kg Intravenous
Subject autologous bone marrow mononuclear cells Cell therapy 1.2e+07 cells/kg Intravenous